Zoledronic acid

Generic Name: Zoledronic acid

Brand Names: Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₀N_₂O_₇P_₂

CAS Number: 118072-93-8

Unique Ingredient Identifier: 70HZ18PH24

Background: Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted FDA approval on 20 August 2001.

Indication: Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Associated Conditions: Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease

Associated Therapies: Bone Mineral Density

Clinical Trials

Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Zoledronic Acid

First Posted Date: 2017-03-23

Last Posted Date: 2021-02-21

Lead Sponsor: Aarhus University Hospital

Target Recruit Count: 61

Registration Number: NCT03087851

Locations: 🇩🇰
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark, Aarhus, Denmark

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Stage III Pancreatic Cancer AJCC v6 and v7
Pancreatic Adenocarcinoma
Stage IB Pancreatic Cancer AJCC v6 and v7
Stage IIA Pancreatic Cancer AJCC v6 and v7
Recurrent Pancreatic Carcinoma
Stage I Pancreatic Cancer AJCC v6 and v7
Stage IA Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7
Stage II Pancreatic Cancer AJCC v6 and v7
Stage IIB Pancreatic Cancer AJCC v6 and v7

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Radiation: Stereotactic Body Radiation Therapy
Drug: Zoledronic Acid

First Posted Date: 2017-03-08

Last Posted Date: 2025-04-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 44

Registration Number: NCT03073785

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: LEM5
Drug: LEM10
Drug: ZOL
Drug: PBO

First Posted Date: 2017-01-02

Last Posted Date: 2019-08-01

Lead Sponsor: Eisai Inc.

Target Recruit Count: 60

Registration Number: NCT03008447

Locations: 🇺🇸
Clinilabs, Inc, New York, New York, United States
🇺🇸
NeuroTrials Research, Inc, Atlanta, Georgia, United States
🇺🇸
Wake Research Assoicates, LLC, Raleigh, North Carolina, United States

and more 1 locations

Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

Phase 3

Completed

Conditions: Serum Markers of Bone Turnover
Prevention of BMD Loss After THR
Functional Outcomes

Interventions: Drug: Placebo
Drug: Aclasta

First Posted Date: 2016-07-20

Last Posted Date: 2016-07-20

Lead Sponsor: Mel Shiuann-Sheng Lee

Target Recruit Count: 62

Registration Number: NCT02838121

Locations: 🇨🇳
Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan

Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors

Phase 2

Completed

Conditions: Gastrointestinal Cancer
Bone Metastasis

Interventions: Drug: Zoledronic acid
Radiation: Radiotherapy

First Posted Date: 2016-05-27

Last Posted Date: 2017-03-29

Lead Sponsor: Severance Hospital

Target Recruit Count: 60

Registration Number: NCT02784652

Locations: 🇰🇷
Severance hospital, Seoul, Korea, Republic of

A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions

Phase 3

Conditions: Osteoarthritis, Knee

Interventions: Drug: Placebo
Drug: AXS-02

First Posted Date: 2016-04-21

Last Posted Date: 2019-01-10

Lead Sponsor: Axsome Therapeutics, Inc.

Target Recruit Count: 346

Registration Number: NCT02746068

Locations: 🇺🇸
Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸
Accord Clinical Research, Port Orange, Florida, United States
🇺🇸
Affinity Clinical Research Institute, Oak Lawn, Illinois, United States